A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

PURPOSE: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial. Methods: Vorinostat was administered orally 400 mg daily, 28 day...

Descripción completa

Detalles Bibliográficos
Autores principales: Goncalves, Priscila H., Heilbrun, Lance K., Barrett, Michael T., Kummar, Shivaani, Hansen, Aaron R., Siu, Lillian L., Piekarz, Richard L., Sukari, Ammar W., Chao, Joseph, Pilat, Mary Jo, Smith, Daryn W., Casetta, Lindsay, Boerner, Scott A., Chen, Alice, Lenkiewicz, Elizabeth, Malasi, Smriti, LoRusso, Patricia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464838/
https://www.ncbi.nlm.nih.gov/pubmed/28415633
http://dx.doi.org/10.18632/oncotarget.16464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464838/
https://www.ncbi.nlm.nih.gov/pubmed/28415633
http://dx.doi.org/10.18632/oncotarget.16464

Ejemplares similares